CCDC105 Activators
CCDC105 can engage in a series of cellular mechanisms to increase the activity of this protein. Forskolin is known to directly activate adenylate cyclase, the enzyme responsible for converting ATP to cyclic AMP (cAMP). The increase in cAMP levels acts as a second messenger, which activates protein kinase A (PKA). Activated PKA can then phosphorylate various proteins, including CCDC105 if it is a PKA substrate. Similarly, IBMX raises intracellular cAMP levels by inhibiting phosphodiesterases, enzymes that degrade cAMP. This inhibition results in sustained cAMP presence and extended PKA activation, potentially influencing CCDC105 activity. Epinephrine and isoproterenol both interact with adrenergic receptors, while PGE2 activates its own G-protein-coupled receptors. These interactions promote adenylate cyclase activity, further amplifying cAMP production and PKA activation, with downstream effects on CCDC105.
Other chemicals operate on similar pathways with slight variations. Anagrelide and rolipram selectively inhibit phosphodiesterase types 3 and 4, respectively, leading to an increase in cAMP levels in specific cellular contexts, which in turn activates PKA and may regulate CCDC105 activity. Beta-adrenergic agonists such as terbutaline, salbutamol, and dobutamine stimulate adenylate cyclase through their receptor-mediated actions, each raising cAMP levels and promoting PKA-mediated phosphorylation processes that can activate CCDC105. Histamine, acting on H2 receptors, and dopamine, through D1-like receptors, also enhance cAMP production, thereby engaging PKA and potentially modifying CCDC105 activity through phosphorylation. These mechanisms, involving various receptors and enzymes, converge on the pivotal role of cAMP and PKA in the regulation of CCDC105 activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to an increase in cAMP by preventing its degradation. This, in turn, activates PKA, which could phosphorylate and activate CCDC105. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine interacts with adrenergic receptors, which can stimulate adenylate cyclase, increase cAMP levels, activate PKA, and potentially lead to the phosphorylation and activation of CCDC105. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G-protein-coupled receptors (GPCRs), leading to adenylate cyclase activation, an increase in cAMP levels, and subsequent PKA activation, which may activate CCDC105 through phosphorylation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which specifically increases cAMP levels in cells, leading to enhanced PKA activity and potential activation of CCDC105. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic beta-adrenergic agonist that stimulates adenylate cyclase activity, raises cAMP levels, and thereby activates PKA, potentially leading to CCDC105 activation. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can stimulate H2 receptors, which activate adenylate cyclase, increase cAMP, activate PKA, and possibly lead to the activation of CCDC105 through phosphorylation. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, leading to increased cAMP levels and subsequent PKA activation, which can phosphorylate and potentially activate CCDC105. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline acts as a beta2-adrenergic agonist, which can lead to adenylate cyclase activation, an increase in cAMP, activation of PKA, and potential activation of CCDC105 through phosphorylation. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine interacts with D1-like receptors, which can increase cAMP levels via adenylate cyclase activation, leading to PKA activation and possible activation of CCDC105. | ||||||
Dobutamine | 34368-04-2 | sc-507555 | 100 mg | $295.00 | ||
Dobutamine acts on beta1-adrenergic receptors, potentially leading to increased cAMP production, PKA activation, and subsequent activation of CCDC105 through phosphorylation. | ||||||